What does PHARM-AD do?

PHARM-AD is filed with the CBE under the catch-all “Overige zakelijke dienstverlening”, a code that says little about what the company actually does. Private Limited, started on 3 October 2009, 1 establishment.

What is the address of PHARM-AD?

The registered office of PHARM-AD is located at Rue Sainte-Gertrude(Piét.) 5, 1370 Jodoigne.

Is PHARM-AD still active?

Yes. According to the CBE (2 November 2026) PHARM-AD is active, legal situation “Normale toestand”, started on 3 October 2009.

Is PHARM-AD registered on Peppol?

Yes, PHARM-AD is registered on the Peppol network with ID 0208:0819236165.

What is the enterprise number of PHARM-AD?

The enterprise number of PHARM-AD is BE0819236165.

When was PHARM-AD founded?

PHARM-AD was founded on 3 October 2009.

Who are the directors of PHARM-AD?

According to the 2025 annual accounts, the directors of PHARM-AD are: Daniel Lasanow, Andrea Lohée.

Is PHARM-AD a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 3 October 2009; 4 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did PHARM-AD make in 2025?

PHARM-AD posted a profit after taxes of € 150,580 in financial year 2025.

What is the revenue of PHARM-AD?

As a small company, PHARM-AD is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 222,322.

PHARM-AD (Private Limited) - Jodoigne - BE0819236165

Dossier PHARM-AD, printed on 2 November 2026 from databakkes.be/en/0819236165/pharm-ad. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

PHARM-AD from Jodoigne, company number BE0819236165, closed financial year 2025 with a result of € 150,580 after tax. For that financial year PHARM-AD recorded a gross margin of € 222,322 and equity of € 476,654. Compared with financial year 2024, the result moved from € 179,337 to € 150,580. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on January 30, 2026.

What it is worth Growing

€ 476,654

▲ 1% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 150,580

▼ 16% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 344,323

▼ 15% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 147,110 paid out

98 % of the profit went to the shareholders, the rest stayed in the company.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Taxes

€ 40,240

▼ 45% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 88,601 Gross margin 2022: € 88,601 First fiscal year in the series	€ 114,332 Gross margin 2023: € 114,332 ▲ 29% vs 2022 (€ 88,601) Favourable step	€ 262,607 Gross margin 2024: € 262,607 ▲ 130% vs 2023 (€ 114,332) Favourable step	€ 222,322 Gross margin 2025: € 222,322 ▼ 15% vs 2024 (€ 262,607) Unfavourable step	▼ 15%
Profit after taxes	€ 57,286 Profit after taxes 2022: € 57,286 First fiscal year in the series	€ 80,487 Profit after taxes 2023: € 80,487 ▲ 41% vs 2022 (€ 57,286) Favourable step	€ 179,337 Profit after taxes 2024: € 179,337 ▲ 123% vs 2023 (€ 80,487) Favourable step	€ 150,580 Profit after taxes 2025: € 150,580 ▼ 16% vs 2024 (€ 179,337) Unfavourable step	▼ 16%
Equity	€ 365,659 Equity 2022: € 365,659 First fiscal year in the series	€ 446,147 Equity 2023: € 446,147 ▲ 22% vs 2022 (€ 365,659) Favourable step	€ 473,184 Equity 2024: € 473,184 ▲ 6% vs 2023 (€ 446,147) Favourable step	€ 476,654 Equity 2025: € 476,654 ▲ 1% vs 2024 (€ 473,184) Favourable step	▲ 1%
Total debts	€ 30,284 Total debts 2022: € 30,284 First fiscal year in the series	€ 44,585 Total debts 2023: € 44,585 ▲ 47% vs 2022 (€ 30,284) Unfavourable step	€ 259,755 Total debts 2024: € 259,755 ▲ € 215,170 vs 2023 (€ 44,585) Unfavourable step	€ 182,653 Total debts 2025: € 182,653 ▼ 30% vs 2024 (€ 259,755) Favourable step	▼ 30%
Cash	€ 174,388 Cash 2022: € 174,388 First fiscal year in the series	€ 246,822 Cash 2023: € 246,822 ▲ 42% vs 2022 (€ 174,388) Favourable step	€ 406,112 Cash 2024: € 406,112 ▲ 65% vs 2023 (€ 246,822) Favourable step	€ 344,323 Cash 2025: € 344,323 ▼ 15% vs 2024 (€ 406,112) Unfavourable step	▼ 15%
Land & buildings	-	-	€ 3,951 Land & buildings 2024: € 3,951 First fiscal year in the series	€ 3,552 Land & buildings 2025: € 3,552 ▼ 10% vs 2024 (€ 3,951) Unchanged	▼ 10%
Retained profit	€ 359,459 Retained profit 2022: € 359,459 First fiscal year in the series	€ 439,947 Retained profit 2023: € 439,947 ▲ 22% vs 2022 (€ 359,459) Favourable step	€ 466,984 Retained profit 2024: € 466,984 ▲ 6% vs 2023 (€ 439,947) Favourable step	€ 470,454 Retained profit 2025: € 470,454 ▲ 1% vs 2024 (€ 466,984) Favourable step	▲ 1%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 0 Dividend 2023: € 0 Unchanged (€ 0) Unchanged	€ 152,300 Dividend 2024: € 152,300 Unchanged (€ 0) Unchanged	€ 147,110 Dividend 2025: € 147,110 ▼ 3% vs 2024 (€ 152,300) Unchanged	▼ 3%
Balance sheet total	€ 395,944 Balance sheet total 2022: € 395,944 First fiscal year in the series	€ 490,732 Balance sheet total 2023: € 490,732 ▲ 24% vs 2022 (€ 395,944) Unchanged	€ 732,939 Balance sheet total 2024: € 732,939 ▲ 49% vs 2023 (€ 490,732) Unchanged	€ 659,306 Balance sheet total 2025: € 659,306 ▼ 10% vs 2024 (€ 732,939) Unchanged	▼ 10%

Key figures of PHARM-AD, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 January 2027.

What happened to PHARM-AD?

What happened at PHARM-AD in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jan 30, 2026 New annual accounts for financial year 2025: profit of € 150,580 (▼ 16% vs 2024). Source: NBB ↗
Oct 3, 2009 New establishment in Jodoigne. KBO
Oct 3, 2009 Start of the company according to the CBE. KBO

In short

From € 57,286 profit in 2022 to € 150,580 profit in 2025.

Paid € 203,484 in corporate taxes since 2022.

Best year ever: 2024, with € 179,337 profit.

Paid out € 299,410 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Daniel Lasanow Andrea Lohée

PHARM-AD

Behind PHARM-AD are Daniel Lasanow and Andrea Lohée.

Directors

According to the 2025 annual accounts

Daniel Lasanow

Director

Andrea Lohée

Director

Establishments

Establishment units

Physical locations of this company

Registered office

Rue Sainte-Gertrude(Piét.) 5

1370 Jodoigne

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

Belgian Pony Games Association

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0819.236.165
VAT number: BE 0819.236.165
Registered office: Rue Sainte-Gertrude(Piét.) 5, 1370 Jodoigne
Names & denominations: PHARM-AD
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 3 October 2009
Peppol: Active · Active since 17 Feb 2026
Activities · NACE: Overige zakelijke dienstverlening, neg

View on CBE Public ↗ Annual accounts (NBB) ↗